Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
79.75
+0.38 (+0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
55
56
Next >
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
February 09, 2023
Via
Benzinga
AstraZeneca Q4 Earnings Beat, Sales Hurt By COVID Jab
February 09, 2023
Core earnings of $1.38 per share declined 17% year over year on a reported basis and 5% at constant exchange rates (CER).
Via
Talk Markets
US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst
February 09, 2023
The see-sawing mood in the market continues as Fed’s data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in...
Via
Benzinga
AstraZeneca Earnings Preview
February 08, 2023
Via
Benzinga
AZN Stock Under Pressure
January 23, 2023
Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses.
Via
Talk Markets
The Top Healthcare Stocks to Buy With $100
January 23, 2023
Don't overlook these big-name foreign healthcare stocks.
Via
The Motley Fool
Beat the Dow Jones With This Unstoppable Dividend Stock
February 08, 2023
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years.
Via
The Motley Fool
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
February 06, 2023
Via
Investor Brand Network
Exposures
COVID-19
Product Safety
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
February 06, 2023
Danaher Corporation (NYSE: DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE: CTLT).
Via
Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.
Via
The Motley Fool
Top 5 Health Care Stocks That May Rally
February 03, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
February 02, 2023
Via
Benzinga
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
February 02, 2023
From
AstraZeneca
Via
Business Wire
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
February 01, 2023
These healthcare titans are poised for a strong showing in 2023 and beyond.
Via
The Motley Fool
These 2 Healthcare Stocks Have Doubled in 2023
February 01, 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.
Via
MarketBeat
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
January 30, 2023
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths.
Via
Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
Could This Vaccine Become Sanofi's Latest Blockbuster?
January 29, 2023
This vaccine candidate could be approved in newborns and infants later this year.
Via
The Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
January 27, 2023
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
Via
The Motley Fool
7 Dividend Stocks to Buy for a Stable Income Stream
January 27, 2023
These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations.
Via
InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
January 26, 2023
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.
Via
The Motley Fool
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
January 23, 2023
From
AstraZeneca
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
January 20, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
January 19, 2023
After years of lab failures, the companies could crack open a multibillion-dollar market.
Via
Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
January 19, 2023
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key...
Via
Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
January 19, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
AbbVie Stock: Dividend King ABBV Overview
January 19, 2023
Via
MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
January 18, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
January 18, 2023
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.